Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas.
lower-grade gliomas
malignant progression-free survival
overall survival
progression-free survival
supratotal resection
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
05 05 2021
05 05 2021
Historique:
pubmed:
14
10
2020
medline:
21
5
2021
entrez:
13
10
2020
Statut:
ppublish
Résumé
Supratotal resection is advocated in lower-grade gliomas (LGGs) based on theoretical advantages but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecularly defined LGGs with oncological outcomes. Included were 460 presumptive LGGs; 404 resected; 347 were LGGs, 319 isocitrate dehydrogenase (IDH)-mutated, 28 wildtype. All patients had clinical, imaging, and molecular data. Resection aimed at supratotal resection without any patient or tumor a priori selection. The association of extent of resection (EOR), categorized on volumetric fluid attenuated inversion recovery images as residual tumor volume, along with postsurgical management with progression-free survival (PFS), malignant (M)PFS, and overall survival (OS) assessed by univariate, multivariate, and propensity score analysis. The study mainly focused on IDH-mutated LGGs, the "typical LGGs." Median follow-up was 6.8 years (interquartile range, 5-8). Out of 319 IDH-mutated LGGs, 190 (59.6%) progressed, median PFS: 4.7 years (95% CI: 4-5.3). Total and supratotal resection obtained in 39% and 35% of patients with IDH1-mutated tumors. In IDH-mutated tumors, most patients in the partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months (95% CI: 25-36) in subtotal, 46 months (95% CI: 38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular subtypes and grade. At random forest analysis, PFS strongly associated with EOR, radiotherapy, and previous treatment. In the propensity score analysis, EOR associated with PFS (hazard ratio, 0.03; 95% CI: 0.01-0.13). MPFS occurred in 32.1% of subtotal total groups; 1 event in supratotal. EOR, grade III, previous treatment correlated to MPFS. At random forest analysis, OS associated with EOR as well. Supratotal resection strongly associated with PFS, MPFS, and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
Sections du résumé
BACKGROUND
Supratotal resection is advocated in lower-grade gliomas (LGGs) based on theoretical advantages but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecularly defined LGGs with oncological outcomes.
METHODS
Included were 460 presumptive LGGs; 404 resected; 347 were LGGs, 319 isocitrate dehydrogenase (IDH)-mutated, 28 wildtype. All patients had clinical, imaging, and molecular data. Resection aimed at supratotal resection without any patient or tumor a priori selection. The association of extent of resection (EOR), categorized on volumetric fluid attenuated inversion recovery images as residual tumor volume, along with postsurgical management with progression-free survival (PFS), malignant (M)PFS, and overall survival (OS) assessed by univariate, multivariate, and propensity score analysis. The study mainly focused on IDH-mutated LGGs, the "typical LGGs."
RESULTS
Median follow-up was 6.8 years (interquartile range, 5-8). Out of 319 IDH-mutated LGGs, 190 (59.6%) progressed, median PFS: 4.7 years (95% CI: 4-5.3). Total and supratotal resection obtained in 39% and 35% of patients with IDH1-mutated tumors. In IDH-mutated tumors, most patients in the partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months (95% CI: 25-36) in subtotal, 46 months (95% CI: 38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular subtypes and grade. At random forest analysis, PFS strongly associated with EOR, radiotherapy, and previous treatment. In the propensity score analysis, EOR associated with PFS (hazard ratio, 0.03; 95% CI: 0.01-0.13). MPFS occurred in 32.1% of subtotal total groups; 1 event in supratotal. EOR, grade III, previous treatment correlated to MPFS. At random forest analysis, OS associated with EOR as well.
CONCLUSIONS
Supratotal resection strongly associated with PFS, MPFS, and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
Identifiants
pubmed: 33049063
pii: 5922564
doi: 10.1093/neuonc/noaa225
pmc: PMC8099476
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-826Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Sci Rep. 2020 Feb 7;10(1):2086
pubmed: 32034238
Neurosurg Clin N Am. 2019 Jan;30(1):55-63
pubmed: 30470405
Acta Neurochir (Wien). 2016 Jan;158(1):51-8
pubmed: 26530708
J Clin Oncol. 2017 Jul 20;35(21):2439-2449
pubmed: 28640707
J Neurosurg. 2011 Aug;115(2):232-9
pubmed: 21548750
Ann Oncol. 2017 Aug 1;28(8):1942-1948
pubmed: 28475680
Acta Neuropathol. 2015 Jun;129(6):867-73
pubmed: 25962792
Neuro Oncol. 2019 Jul 11;21(7):837-853
pubmed: 30753579
J Clin Oncol. 2012 Jul 10;30(20):2559-65
pubmed: 22529254
Nat Rev Neurol. 2017 Jun;13(6):340-351
pubmed: 28497806
J Neurosurg. 2011 Nov;115(5):948-65
pubmed: 22043865
Neurochirurgie. 2013 Feb;59(1):2-8
pubmed: 23410764
J Neurosurg. 2019 May 17;132(6):1692-1705
pubmed: 31100730
J Neurosurg Sci. 2020 Aug;64(4):313-334
pubmed: 32347684
Neurology. 2010 May 25;74(21):1724-31
pubmed: 20498440
Neuro Oncol. 2018 Jan 10;20(1):103-112
pubmed: 29016833
J Neurooncol. 2015 Dec;125(3):503-30
pubmed: 26530265
Adv Tech Stand Neurosurg. 2010;35:113-57
pubmed: 20102113
Am Soc Clin Oncol Educ Book. 2019 Jan;39:133-145
pubmed: 31099638
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
J Neurosurg. 2013 Jun;118(6):1157-68
pubmed: 23495881
Neuro Oncol. 2014 Aug;16(8):1110-28
pubmed: 24500420
JAMA. 2012 Nov 14;308(18):1881-8
pubmed: 23099483
Acta Neuropathol. 2015 May;129(5):679-93
pubmed: 25783747